ACOR Acorda Therapeutics, Inc.

+0  (1%)
Previous Close 26.85
Open 26.85
Price To book 1.85
Market Cap 1.23B
Shares 45,667,000
Volume 530,164
Short Ratio 4.63
Av. Daily Volume 852,903

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Improve walking in patients with multiple sclerosis
Phase 2 to be initiated by the end of 2017.
Phase 3 data due 1Q 2018.
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Post stroke deficits
Phase 3 data released February 9, 2017 - primary endpoint met.
OFF episodes of Parkinson’s disease (PD)

Latest News

  1. Why Is Acorda (ACOR) Up 10.6% Since the Last Earnings Report?
  2. Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise
  3. Acorda Launches Alexa Skill in Conjunction with MS Awareness Month
  4. Acorda Therapeutics (ACOR) Jumps: Stock Adds 6.5% in Session
  5. ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  6. Patent Trials and Appeal Board (PTAB) Upholds Four AMPYRA® Patents
  7. Acorda Stock Jumps Following Patent Challenge Win
  9. ACORDA THERAPEUTICS INC Files SEC form 10-K, Annual Report
  10. Acorda to Present at the Cowen and Company 37th Annual Healthcare Conference
  11. Implied Volatility Surging for Acorda Therapeutics (ACOR) Stock Options
  12. Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors
  13. Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR)
  14. Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017
  15. Acorda Must Stave Off Mylan, Teva Generics To Protect Ampyra: RBC
  16. (2/15) Today's Top 10 Long/Short Estimize Signal Scores
  17. Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017
  18. Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4
  19. Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.
  20. Acorda Therapeutics upgraded by Goldman